IDO1 and cancer: Silencing of IDO in ovarian cancer cells enhances cancer cell sensitivity to NK cells in vitro, and in vivo and manifests as inhibition of tumor growth, reduction of peritoneal dissemination, and promotion of NK cell accumulation in the tumor stroma [76].